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ABSTRACT
166Holmium-DOTMP is a beta-emitting radiophosphonate that localizes specifically to the bone surfaces and
can deliver high-dose radiation to the bone marrow. Phase I/II trials showed feasibility and tolerability when
combined with high-dose melphalan with or without total-body irradiation (TBI) in patients with multiple
myeloma (MM) undergoing autologous stem cell transplantation (ASCT). The purpose of this study was to
define the potential impact of 166Holmium-DOTMP on outcomes in patients with MM undergoing ASCT.
Retrospective review of transplant outcomes among patients withMMwho received an ASCT between January
1998 to December 2001 with either melphalan 200 mg/m2 or a 166Holmium-DOTMP containing regimen as
part of their initial therapy. Univariate analysis was performed for response, overall survival (OS), and event
free survival (EFS). One hundred four patients were identified, of which 41 received a 166Holmium-DOTMP
containing regimen and 63 received melphalan alone. The 166Holmium-DOTMP patients were divided into 2
groups according to the dose received (<2400 mCi versus >2400mCi). The 166Holmium-DOTMP group had
a trend towards a higher complete remission (CR) rate compared to patients receiving melphalan alone (51%
versus 32%). The median EFS for the low-dose 166Holmium-DOTMP, the high-dose 166Holmium-DOTMP,
and melphalan alone was 30, 23, and 19 months, respectively; the OS rate at 5 years for the 3 groups was 61%,
40%, and 43%, respectively. 166Holmium-DOTMP, in combination with high-dose melphalan, can result in
higher CR rates when given in optimal doses (<2400 mCi) when compared to melphalan alone, and should be
further tested in phase III trials in patients with MM undergoing ASCT.
© 2007 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Multiple myeloma (MM) is a clonal B cell disor-
er, with a gradually progressive natural history and a
edian survival of 3 years [1]. Conventional doses of
hemotherapy only rarely result in complete remis-
ion (CR); on the other hand, high-dose chemother- bpy with autologous stem cell transplantation
ASCT) has been shown to improve complete re-
ission (CR) rates, event free survival (EFS), and
verall survival (OS) in selected patients, especially
hen performed early in the course of the disease
2,3]. High-dose melphalan, with or without total
ody irradiation (TBI), is the most commonly used
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A. V. Christoforidou et al.544onditioning regimen leading to CR rates of up to
0% after a single ASCT [4,5].
Although MM is a radiosensitive malignancy, TBI
as been shown to add toxicity without improving
urvival compared to patients treated with melphalan
lone [6]. The main drawback of external beam radi-
tion has been the toxicities associated with radiation
f nontarget tissues, particularly the lung, liver, kid-
ey, and nervous system [6,7]. Targeted radiotherapy
esulting in localized delivery of radiation to the skel-
ton could allow substantial increases in radiation de-
ivery to bone and bone marrow, whereas limiting the
ystemic toxicities observed with TBI. This approach
as been made possible because of the development of
one-seeking radioisotopes that result from the che-
ation of radioisotopes with phosphonates that bind
ightly to trabecular bone. These bone-seeking radio-
sotopes allow for delivery of substantial amounts of
adiation to the bone and marrow space, and have
een shown to be effective for palliative therapy of
one metastasis [8-11]. The experience with bone-
eeking radioisotopes for palliative therapy of bone
etastasis demonstrated that high doses of radiother-
py could be selectively and effectively delivered to the
one, sparing nontarget organs; the observation that
yelosuppression was the most common toxicity also
uggested the potential role of this therapeutic modal-
ty for treatment of malignant hematologic disorders
f the bone marrow, and as part of high-dose therapy
onditioning regimens [12-14].
Holmium-166 (166Ho) is a beta-emitter with high
nergy (maximum effect 1.85 MeV) and a relatively
hort half-life of 26.8 hours. 166Ho also has a minor
amma component, which allows for simultaneous
maging and dosimetry studies. In an effort to explore
lternative ways to deliver radiotherapy along with the
onditioning regimens, the radioactive agent 166Ho
as conjugated to the phosphonate ethylenediamine-
etramethylenephosphonic acid (DOTMP). The com-
ound 166Ho-DOTMP was used in 1 phase I single-
enter study and 2 phase I/II multicenter studies in
atients with MM receiving high-dose chemotherapy
ollowed by ASCT, conducted at the University of
exas M.D. Anderson Cancer Center, Fred Hutchin-
on Cancer Research Center, and the University of
iami [15-17].
Patients treated in the setting of these trials have
ow been followed for an average of 4 years, and thus
he potential impact of 166Ho-DOTMP on long-term
utcomes in patients with MM can be assessed. To
valuate the impact on remission rates and survival of
66Ho-DOTMP containing conditioning regimens
e performed a retrospective analysis of patients treated
n any 166Ho-DOTMP containing protocol and com-
ared it to the outcomes of patients undergoing
SCT for MM with melphalan 200 mg/m2 during the mame time frame. Herein are the results of this anal-
sis.
ATIENTS AND METHODS
election Criteria
Patients were selected for review from the Uni-
ersity of Texas M.D. Anderson Cancer Center data-
ase if they fulﬁlled all of the following criteria: diag-
osis of MM, treated with high-dose therapy followed
y a single ASCT for either ﬁrst remission consoli-
ation or primary refractory disease between Janu-
ry 1998 and December 2001 and conditioned with
ither melphalan 200 mg/m2 or a 166Ho-DOTMP
ontaining regimen.
onditioning Regimen
Two different 166Ho-DOTMP protocols were
pen during the time frame analyzed: protocol
M98-108 consisted of 800 cGy of TBI given as 4
aily 200-cGy fractions, together with 40 mg/m2 mel-
halan and 166Ho-DOTMP given at different doses
argeted to deliver either 20, 30, or 40 Gy to the bone
arrow, and protocol DM98-109, which consisted of
40 mg/m2 or 200 mg/m2 of melphalan plus 166Ho-
OTMP, also given in escalating doses calculated to
eliver 20, 30, or 40 cGy to the red marrow.
166Ho-DOTMP therapy has been previously de-
cribed in detail [16]. In brief, a therapy dose of
66Ho-DOTMP was administered 7 to 10 days prior
o the expected transplantation date, following dosi-
etric calculations, which were done using a tracer
0-mCi dose in each patient, to deliver an actual bone
arrow dose of 20, 30, or 40 cGy. Melphalan was
iven as a single or 2-day course. Patients registered
n Protocol DM98-108 also received TBI 800 cGy in
fractions. Eligibility for all trials were similar, with
he exception that patients receiving 166Ho-DOTMP
ogether with TBI had to be55 years of age; patients
reated with high-dose melphalan alone during the
tudy period did so because of patient or physician
reference or lack of insurance approval to participate
n the 166Ho-DOTMP trials. All patients received
tandard posttransplantation supportive care accord-
ng to institutional guidelines for ASCT. Protocols
ere institutionally approved, and all patients signed
ritten informed consent. Approval for this retrospec-
ive study was obtained by the institutional review
oard as per institutional guidelines.
esponse Criteria
The EBMT/ABMTR response criteria were used
o assess response [18]. In brief, CR was deﬁned as the
omplete disappearance of monoclonal protein from
oth serum and urine conﬁrmed by 2 negative im-
une ﬁxation studies performed at least 6 weeks apart
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Targeted Skeletal Radiotherapy with 166Holmium-DOTMP 545nd 5% plasma cells in bone marrow biopsy. Partial
esponse was deﬁned as a 50% reduction of serum
araprotein and a 90% reduction in urine parapro-
ein for at least 6 weeks or a 50% reduction in bone
arrow plasma cells in patients with nonsecretory
yeloma. Relapse was conﬁrmed by the reappearance
f paraprotein by immunoﬁxation or electrophoresis
r by the worsening or the appearance of new lytic
esions, hypercalcemia, or plasmacytomas or a 25%
ncrease in the level of serum or urine paraprotein in
t least 2 distinct measurements.
Patients maintaining the same response status as in
he pretransplant period were characterized as having
chieved continuous CR (CCR) or continuous partial
emission (CPR). Response was determined as the
est response at 3 to 12 months posttransplant, and
as based on the ﬁrst of the 2 lowest consecutive
araprotein level estimations, regardless of the use of
aintenance therapy and prior to any disease progres-
ion.
tatistical Analysis
For statistical analysis we deﬁned 3 distinct
roups of patients: patients who were conditioned
ith a 166Ho-DOTMP containing protocol and re-
eived 2400 mCi (group A), patients who were con-
itioned with a 166Ho-DOTMP containing protocol
nd received 2400 mCi or more (group B), and pa-
ients conditioned with melphalan 200 mg/m2 only
group C). The dose of 2400 mCi represents the
edian 166Ho-DOTMP dose delivered, and it was
rbitrarily used to have an adequate number of pa-
ients in each group for statistical purposes.
Pretransplant patient characteristics were com-
ared using the Kruskal-Wallis or the 2 tests for the
umeric and the categoric variables, respectively. Sta-
istical comparisons of response were based on the 2
est. Beta 2 microglobulin and albumin levels at the
ime of diagnosis were unavailable in 21 and 33 pa-
able 1. Patient Characteristics
Group A 166Ho-DOTMP
<2400 mCi
Group
>
o. of patients 21
Age median (years) 52.5 (45-61)
% Male 57
% IgA 33
% DS III at diagnosis 43
2M at SCT
% <3.5 mg/L 71
% >3.5 mg/L 19
lbumin at SCT
% <3.5 g/dL 19
% >3.5 g/dL 81
% Primary refractory 38
S indicates Durie Salmon; SCT, stem cell transplant.
Kruskal-Wallis.ients, respectively, and thus could not be analyzed in
he univariate or multivariate analysis. Survival was
stimated by the Kaplan-Meier method and compared
sing the log-rank test [19-21]. Analysis of survival
as based on the proportional hazards regression
odel. The following parameters were analyzed in
nivariate fashion for effect on OS and EFS: age, Beta
microglobulin, albumin, International Staging Sys-
em (ISS) [22], Durie-Salmon stage [23], immuno-
lobulin isotype, disease response to induction, and
onditioning protocol. Analysis was performed using
he SPSS v14.0 software.
ESULTS
atient Characteristics
One hundred four patients were identiﬁed who
ulﬁlled our criteria; 21 patients had received a con-
itioning regimen with a dose of 166Ho-DOTMP of
2400 mCi (group A), 20 patients received a condi-
ioning regimen with a dose of 2400 mCi or greater of
66Ho-DOTMP (group B), and 63 received high-dose
elphalan alone at a dose of 200 mg/m2 (group C).
ixteen patients in the 166Ho-DOTMP group also
eceived 8 Gy TBI: 9 in group A, and 7 in group B.
66Ho-DOTMP dose administered ranged from 460
o 4476 mCi. Patient characteristics are shown in
etail in Table 1. In brief, there were no signiﬁcant
ifference among the groups regarding median age
nd gender. There was a higher proportion of patients
ith IgA myeloma in the 166Ho-DOTMP groups, and
higher proportion of patients with Durie Stage III
isease in group C. Among patients in whom Beta 2
icroglobulin and albumin values at diagnosis were
vailable, Beta 2 microglobulin levels were similar in
ll 3 groups (3.15, 3.25, and 3.5 for groups A, B, and
, respectively), whereas albumin values were lower in
roup C. Because of the large number of missing
o-DOTMP
mCi
Group C Melphalan
200 mg/m2
P-value Group A versus
Group C
63
64) 55.5 (35-69) NS
62 NS
14 .03
67 .14
62 NS
33
30 NS
70
26 NSB 166H
2400
20
53 (36-
75
40
55
80
20
35
65
25
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A. V. Christoforidou et al.546alues, no formal comparison regarding these vari-
bles was made.
esponse
As of May 2005, the median follow-up was 43.7
onths, ranging from 2.3 to 80 months. The patient
ith the short 2.3-month follow-up was an overseas
atient who was lost to follow-up and was censored at
he time of his last visit. Two patients were nonevaluable
ecause of the lack of a second protein electrophoresis
r immunoﬁxation studies to conﬁrm response, and
ere classiﬁed as nonresponders.
Table 2 summarizes transplant outcomes. Objective
esponse (CR plus PR) was similar in the 3 groups (95%,
0%, and 92%). There was a trend towards a higher rate
f conversion to CR in the 166Ho-DOTMP-containing
roups (55% and 48% versus 32%). Of note, 75% of
atients with partial response and 25% of the primary
efractory patients attained a CR in group A compared
o 40% and 12%, respectively, in group C. Nonre-
apse mortality (NRM) rates were similar for group A
nd group C and signiﬁcantly less than the 20% ob-
erved in group B, who received the higher dose
66Ho-DOTMP.
able 2. Response to Transplantation
Group A 166Ho-DOTMP
<2400 mCi
Group
R rate % 95
R rate %* 57
onversion to CR % 55
R rate %† 38
RM % (1‡) 5
edian OS in months NR
edian EFS in months 30 (4-57)
R indicates complete remission; OR, overall remission; PR, parti
CR  CCR.
PR  CPR.
Number of patients.Figure 1. OveralS and EFS
Fourteen patients (67%) of the 21 treated in
roup A were alive at the time of the analysis, as well
s 7 patients in group B, and 35 (56%) in group C.
he median survival time, estimated by the Kaplan-
eier method, has not been reached for group A,
hereas it is 31 months (range 14-49) for patients in
roup B, and 52 months (range 44-61) for patients
n group C (Table 2) Although not statistically
igniﬁcant, the 5-year OS for patients in group A
as superior to that in patients in groups B and C,
s shown in Figure 1.
In the last follow-up, 9 patients (43%) from group
, 16 (80%) from group B, and 46 (73%) from group
have progressed. Of those, 6 patients from the ﬁrst
roup, 9 from second group, and 26 from the third
roup have died. The median EFS was 30, 23, and 19
onths, respectively.
rognostic Factor Analysis
An elevated Beta 2 microglobulin level and ISS
t SCT were the only 2 signiﬁcant predictors of OS
nd progression-free survival on univariate analysis
o-DOTMP
mCi
Group C melphalan 200
mg/m2
P Group A versus
Group C
92 .5
36 .08
32 .04
56 .13
) 20 (2‡) 3.2 .8
-49) 52 (44-61)
0) 19 (10-29)
ssion; OS, overall survival; EFS, event-free survival.B 166H
>2400
90
50
48
40
(4‡
31 (14
23 (1-3
al remil survival.
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Targeted Skeletal Radiotherapy with 166Holmium-DOTMP 547Table 3). Rates of failure were almost double in
atients with Beta 2 microglobulin levels of 3.5 g/dL
r higher compared to those with levels 3.5 g/dL,
nd in patients classiﬁed as ISS stage II-III compared
o those with ISS stage I. Conditioning with 166Ho-
OTMP was associated with a lower failure rate com-
ared with melphalan alone, yet this effect did not
each statistical signiﬁcance (Table 4). Because Beta 2
icroglobulin is a part of the ISS, the independent
ffects of these 2 factors could not be evaluated. When
otential confounding effects were evaluated in a bi-
ariate model including conditioning regimen and ISS
tage I results were consistent with univariate analysis
ndicating that the effects of these factors are indepen-
ent. Similarly, results were consistent with univariate
nalysis when ISS stage I was substituted with elevated
eta 2 microglobulin level in the bivariate model (data
ot shown).
ISCUSSION
166Ho-DOTMP is a beta-emitting radiophospho-
ate that localizes to areas of active bone turnover and
an be a useful agent in the preparative regimens for
SCT in patients with MM. The results of a multi-
enter phase I/II trial have been previously reported
17]. The acute toxicity proﬁle was no different from
able 3. Prognostic Factors for Overall Survival Groups A and C Only
Variable N Univariate H
onditioning Regimen
Group C 63 ref
Group A 21 0.63
ender
Female 33 ref
Male 51 0.7
ge
<50 23 ref
51-55 19 0.8
56-60 26 1.5
>60 16 0.6
isease status prior to SCT
1ry refractory 24 ref
1st remission 55 1.1
Complete remission 5 1.2
eta 2 microglobulin at SCT
<3.5 54
>3.5 25 ref
Unknown 5 2.5
lbumin at SCT
<3.5 23 ref
>3.5 61 0.6
nternational staging system at SCT
I 43 ref
II 24 2.0
III 11 2.1
Unknown 6
I versus II-III 0.6I indicates conﬁdence interval; HR, hazard ratio; SCT, stem cell transplelphalan alone, and engraftment was prompt in most
f the patients. However, the development of late
enal dysfunction in 18% of all patients demonstrated
hat targeting a speciﬁc marrow dose without limiting
he total amount of 166Ho-DOTMP delivered would
ot be feasible. In the phase I/II trials of 166Ho-
OTMP grade 3-4 renal toxicity was seen primarily
n patients receiving 1200 mCi/m2 of 166Ho-
OTMP.
In the present study, we retrospectively analyzed
he transplant outcomes of the 41 patients treated in
single center with a 166Ho-DOTMP-containing
egimen between January 1998 and December 2001
groups A and B), and compared them with the
ransplant outcomes of 63 patients treated with
igh-dose melphalan followed by ASCT in the same
ime frame (group C). To evaluate the effect of 166Ho-
OTMP dosing on outcomes we analyzed separately
atients who received 2400 mCi of 166Ho-DOTMP
group A) and those who received 2400 mCi or more
group B).
Patients in group A had a similar NRM rate as
atients receiving melphalan alone during the same
ime period (5% and 3.2%, respectively). Patients in
roup A also had a trend towards a high rate of
onversion to CR and a longer EFS (median 30
onths versus 19 months) and OS (61% versus 42%
95% CI Multivariate HR 95% CI P
0.3-1.5 0.7 0.3-1.6 .4
0.3-1.4
0.3-2.2
0.7-3.5
0.2-1.9
0.5-2.5
0.25-5.4
1.2-4.7P  .02
0.3-1.05P  .07
0.9-4.3P  .08
0.8-5.6P  .12
0.2-0.98P  .045 0.5 0.2-1.03 .06Rant.
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A. V. Christoforidou et al.548t 5 years) than patients in group C, suggesting that
he doses of 2400 mCi or less are the most appropriate
o exploit the therapeutic effects of this agent. On
ultivariate analysis only, the ISS score at the time of
CT was associated with a signiﬁcant improved sur-
ival. This observation is interesting, because the ISS
core was developed as a prognostic factor for patients
ith newly diagnosed myeloma, and the prognostic
alue of pretransplant ISS has not been established.
e were unable to assess the impact of ISS at the time
f diagnosis because of the large proportion of pa-
ients in whom Beta 2 microglobulin at the time of
iagnosis was unavailable.
There is a growing experience with targeted skel-
tal radiotherapy in human malignancies. Apart from
66Ho-DOTMP, 153Sm-EDTMP is currently being
ested in patients with MM in combination with high-
ose melphalan. The toxicity proﬁle of red marrow
oses up to 40 Gy given in 18 patients was excellent
fter a median follow-up of 31 months [24].
These results, although not statistically signiﬁcant
ecause of the low patient number and the nonuni-
orm treatment strategy, provide encouraging infor-
ation and support further exploration of targeted
keletal radiotherapy as a component of the prepara-
able 4. Prognostic Factors for Event-Free Survival Groups A and C O
Variable N Univariate H
onditioning regimen
Group C 63 ref
Group A 21 0.6
ender
Female 33 ref
Male 51 1.3
ge
<50 23 ref
51-55 19 0.8
56-60 26 1.2
>60 16 0.7
isease status prior to SCT
1 ry Refractory 24 ref
1st Remission 55 1.2
Complete remission 5 0.5
eta 2 microglobulin at SCT
<3.5 54 ref
>3.5 25 2.2
Unknown 5
lbumin at SCT
<3.5 23 ref
>3.5 61 0.6
nternational staging system at SCT
I 43 ref
II 24 2.2
III 11 2.1
Unknown 6 0.6
I versus II-III
I indicates conﬁdence interval; HR, hazard ratio; SCT, stem cellive regimens of ASCT.CKNOWLEDGMENTS
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